Savara Inc Peo Actually Paid Comp Amt
Savara Inc (SVRA) reported Peo Actually Paid Comp Amt of $9.89 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-24.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-24
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2025-12-31 | $9.89M DEF 14A · filed 2026-04-24 |
| 2024-12-31 | $3.97M DEF 14A · filed 2026-04-24 |
| 2023-12-31 | $5.66M DEF 14A · filed 2026-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |